Stopping Muscular Dystrophy with a ‘Backup’ Protein

Research and Innovation / November 3, 2026

Share:
Author:
Frank Otto, Penn Medicine

A new use of CRISPR gene editing halted and even reversed the progression of a model of Duchene muscular dystrophy in mice, according to work led by scientists at the Perelman School of Medicine of the University of Pennsylvania. The technique boosted a protein, utrophin, as a stand-in to take on the job of a different protein, dystrophin, which helps maintain healthy muscles and is in short supply in those with muscular dystrophy. This work was published in Molecular Therapy Advances.

“Unfortunately, there are currently no safe and effective therapies that can cure Duchenne muscular dystrophy, or even treat everyone with the disease equally,” said senior author Tejvir S. Khurana, MD, PhD, a professor of Physiology and a member of the Pennsylvania Muscle Institute. “But we believe that combining a pair of delivery systems already in use has great therapeutic potential and could lead to a significant change in how we treat this disease.”

This system that Khurana and his team used combined the expertise of Drew Weissman, MD, PhD, the Roberts Family Professor in Vaccine Research, who won the Nobel Prize in 2023 for his work in developing mRNA systems that code the body cells to produce certain proteins, and that of Michael Mitchell, PhD, the Hibbert Professor of Bioengineering, who developed a delivery system that uses fatty compounds—called lipid nanoparticles—to encase and bring cargo to targeted cells.

Read More at Penn Today
Story Tags